Acelyrin, Inc. (SLRN)
NASDAQ: SLRN · IEX Real-Time Price · USD
6.51
-0.02 (-0.31%)
At close: Jul 19, 2024, 4:00 PM
6.57
+0.06 (0.92%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Acelyrin Employees
Acelyrin had 135 employees as of December 31, 2023. The number of employees increased by 88 or 187.23% compared to the previous year.
Employees
135
Change (1Y)
88
Growth (1Y)
187.23%
Revenue / Employee
n/a
Profits / Employee
-$1,778,993
Market Cap
644.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 135 | 88 | 187.23% |
| Dec 31, 2022 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aveanna Healthcare Holdings | 33,500 |
| Pediatrix Medical Group | 5,450 |
| Fulgent Genetics | 1,184 |
| Exscientia | 483 |
| Phathom Pharmaceuticals | 452 |
| Prime Medicine | 234 |
| IGM Biosciences | 224 |
| UroGen Pharma | 201 |
SLRN News
- 7 weeks ago - ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 - GlobeNewsWire
- 2 months ago - ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones - GlobeNewsWire
- 2 months ago - ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 - GlobeNewsWire
- 4 months ago - ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights - GlobeNewsWire
- 4 months ago - ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis - GlobeNewsWire
- 4 months ago - ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients - GlobeNewsWire
- 5 months ago - ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications - GlobeNewsWire
- 6 months ago - SHAREHOLDER ALERT: Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN) Investors of a Class Action Lawsuit and Upcoming Deadline - PRNewsWire